Tiziana Life Sciences Ltd

Tiziana Life Sciences Ltd. operates as a clinical stage biotechnology company. It engages in the research and development of biotechnological and pharmaceutical products. The firm specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for secondary progressive multiple Sclerosis, Crohn's disease and KRAS+ NSCLC. The company was founded by Gabriele Marco Antonio Cerrone on February 11, 1998 and is headquartered in London, the United Kingdom.

Tiziana Life Sciences Ltd. is a clinical-stage biotechnology company, which engages in the research and development of biotechnological and pharmaceutical products. It specializes in developing transformative therapies for neurodegenerative and lung diseases. The company was founded by Gabriele Marco Antonio Cerrone on February 11, 1998 and is headquartered in London, the United Kingdom.

Tiziana Life Sciences Ltd (NASDAQ:TLSA) shares rose 8% to $0.86 in midday trading on Monday after the clinical-stage biopharmaceutical company revealed six-month data that showed positive clinical improvements related to Modified Fatigue Impact Scale (MFIS) scores and similar important clinical measures of physical function in foralumab-treated, non-active Secondary Progressive Multiple Sclerosis (na-SPMS) patients participating in an Expanded Access (EA) Program.  Tiziana noted that numeric improvements were seen across key multiple sclerosis measures, including the Modified Fatigue Impact Scale, Expanded Disability Status Scale, Timed 25-Foot Walk test, Pyramidal Scores and NeuroQoL Fatigue scores.

Tiziana Life Sciences stock continues to climb; COO ‘excited' by recent results

Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced six-month data showing positive clinical improvements related to Modified Fatigue Impact Scale (MFIS) scores and similar important clinical measures of physical function in foralumab-treated, non-active Secondary Progressive Multiple Sclerosis (na-SPMS) patients participating in an Expanded Access (EA) Program.  The clinical-stage biopharmaceutical company said numeric improvements were seen across key multiple sclerosis measures, including the Modified Fatigue Impact Scale, Expanded Disability Status Scale, Timed 25-Foot Walk test, Pyramidal Scores and NeuroQoL Fatigue scores.

Tiziana Life Sciences reveals positive clinical results for MS patients treated with Foralumab

NEW YORK, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced six-month data showing positive clinical improvements related to Modified Fatigue Impact Scale (MFIS) scores and similar important clinical measures of physical function in foralumab-treated, non-active Secondary Progressive Multiple Sclerosis (na-SPMS) patients participating in an Expanded Access (EA) Program.   This follows on from previously announced positive six-month PET scan data which was presented at ECTRIMS 2023.

Tiziana Life Sciences Announces Positive Six-Month Clinical Results in Multiple Sclerosis Patients Treated with Intranasal Foralumab

In an exclusive interview with Thomas Warner from Proactive, Matthew Davis, the chief medical officer and chief operating officer of Tiziana Life Sciences Ltd (NASDAQ:TLSA), discussed the company's latest six-month PET scan data for treating non-active secondary progressive multiple sclerosis (MS). The data show improvements in five out of six patients, supporting the drug's hypothesis published in the Proceedings of the National Academy of Science.

Tiziana Life Sciences' Matthew Davis discusses significance of latest MS treatment data

Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that a reduction in activated microglia, as seen in six-month Positron Emission Tomography (PET) scans, has now been observed in a total of five of the six patients with non-active secondary-progressive multiple sclerosis (na-SPMS) treated with intranasal Foralumab in its Expanded Access Program (EAP).   The clinical-stage biopharmaceutical company said activated microglia are believed to play a prominent role in the pathogenesis of neuroinflammatory and neurodegenerative diseases including multiple sclerosis (MS), Alzheimer's disease, and amyotrophic lateral sclerosis, or ALS.

Tiziana Life Sciences reveals positive PET scan results with Foralumab to treat MS patients

NEW YORK, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that a reduction in activated microglia, as seen in six-month Positron Emission Tomography (PET) scans, has now been observed in a total of five of the six patients with non-active secondary-progressive multiple sclerosis (na-SPMS) treated with intranasal foralumab in its Expanded Access Program (EAP). Activated microglia are believed to play a prominent role in the pathogenesis of neuroinflammatory and neurodegenerative diseases including multiple sclerosis, Alzheimer's disease, and amyotrophic lateral sclerosis, or ALS.

Tiziana Announces Positive Qualitative Six-Month PET Scan Results With Intranasal Foralumab Treating Multiple Sclerosis Patients Diagnosed With Non-Active Secondary Progressive MS (na-SPMS)

Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced that a late breaking poster titled, "Treatment Of Six Non-Active Secondary Progressive MS With Nasal Anti-CD3 Monoclonal Antibody (Foralumab): Safety, Biomarker, And Disability Outcomes," will be presented at the 39th Congress of the European Committee for Treatment and Research of Multiple Sclerosis (ECTRIMS) being held in Milan, Italy, from October 11-13, 2023.  The clinical-stage biopharmaceutical company said ECTRIMS is a non-profit organization that serves as Europe's and the world's largest professional organization dedicated to the understanding and treatment of MS.

Tiziana Life Sciences to present MS treatment at ECTRIMS Annual Congress

Late-breaking poster to be presented titled: “Treatment Of Six Non-Active Secondary Progressive MS With Nasal Anti-CD3 Monoclonal Antibody (Foralumab): Safety, Biomarker, And Disability Outcomes” NEW YORK, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced a late breaking poster titled, “Treatment Of Six Non-Active Secondary Progressive MS With Nasal Anti-CD3 Monoclonal Antibody (Foralumab): Safety, Biomarker, And Disability Outcomes”, will be presented at the 39th Congress of the European Committee for Treatment and Research of Multiple Sclerosis (ECTRIMS) being held in Milan, Italy, October 11-13, 2023.

Tiziana Announces Presentation of Six-Month Safety and Biomarker Data for Intranasal Foralumab in Patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) at the ECTRIMS Annual Congress

Tiziana Life Sciences Ltd (NASDAQ:TLSA) said it has commenced site initiation for its lead intranasal foralumab program entering Phase 2a clinical testing in non-active Secondary Progressive Multiple Sclerosis (na-SPMS) patients. Following an investigator's meeting with principal investigators at Brigham and Women's Hospital, a founding member of Mass General Brigham Healthcare System, the biotechnology company announced in a statement that six to 10 new clinical trial sites will be recruited, in total.

Tiziana Life Sciences initiates multi-center Phase 2a clinical trial of intranasal foralumab for na-SPMS

NEW YORK, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of delivery, today announced that it held an Investigator's Meeting with principal investigators at Brigham and Women's Hospital, a founding member of Mass General Brigham Healthcare System, to begin site initiation for its lead intranasal foralumab program entering Phase 2a clinical testing in non-active Secondary Progressive Multiple Sclerosis (na-SPMS) patients. In total, six to ten new clinical trial sites will be recruited.

Tiziana Life Sciences Initiates Multi-Center Phase 2a Clinical Trial of Intranasal Foralumab for Non-Active Secondary Progressive Multiple Sclerosis

NEW YORK, Sept. 08, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that the Company will virtually present and host one-on-one meetings at the H.C. Wainwright 25th Annual Global Investment Conference, being held September 11-13, 2023.

Tiziana Life Sciences to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

Tiziana Life Sciences Ltd (NASDAQ:TLSA) said a study validating the mechanism of action of its drug candidate intranasal foralumab in Alzheimer's Disease has been published in the prestigious journal Proceedings of the National Academy of Sciences (PNAS). The company noted that the publication, “Nasal Administration of anti-CD3 monoclonal antibody (mAb) ameliorates disease in a mouse model of Alzheimer's disease”, is the second related to the intranasal administration of anti-CD3 monoclonal antibody to be published in PNAS this year.

Tiziana Life Sciences highlights publication of promising intranasal foralumab in Alzheimer's study results

NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced acceptance of a publication, “Nasal Administration of anti-CD3 monoclonal antibody (mAb) ameliorates disease in a mouse model of Alzheimer's disease”, in the preeminent1 journal, Proceedings of the National Academy of Sciences (PNAS), that supports foralumab's mechanism as a potential treatment for Alzheimer's disease (AD), a difficult-to-treat neuroinflammatory disease.2   This is the second publication pertaining to intranasal administration of anti-CD3 monoclonal antibody this year to be published in PNAS.3

Study Validating MoA of Intranasal Foralumab in Alzheimer's Disease Published in the Prestigious Journal PNAS, Following FDA IND Clearance

NEW YORK, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, is pleased to announce that it has appointed William A. Clementi, Pharm.D., FCP as Chief Development Officer. Dr. Clementi will formally take up the CDO role effective September 1, 2023. In this role, Dr. Clementi will be responsible for overseeing the company's development strategies and advancing its portfolio of groundbreaking therapeutic candidates.

Tiziana Life Sciences Announces Appointment of William A. Clementi as Chief Development Officer

Tiziana Life Sciences Ltd (NASDAQ:TLSA) said its investigational therapeutic foralumab will be highlighted by its scientific advisory board chairman Dr. Howard Weiner during an oral presentation at the 16th International Society of Neuroimmunology (ISNI) Congress in Quebec City, Canada.

Tiziana Life Sciences investigational therapeutic foralumab in the spotlight at neuroimmunology event

NEW YORK, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced an oral presentation of “Nasal anti-CD3 mAb induces Tregs that dampen microglial activation and treat neuroinflammatory diseases including MS, AD and ALS” at the 16th International Society of Neuroimmunology (ISNI) Congress in Quebec City, Canada, being held August 21-24, 2023. Dr. Weiner's live presentation is scheduled for 11:42 a.m. ET on August 24, 2023.

Tiziana Life Sciences Announces Foralumab Presentation by Dr. Howard Weiner at the Annual Meeting of the International Society of Neuroimmunology

Tiziana Life Sciences Ltd (NASDAQ:TLSA) expects to report initial results from its Phase 2 trial of its investigational therapeutic intranasal foralumab for Alzheimer's disease in the fall of 2024, neurology expert and chairman of the company's scientific advisory board Dr. Howard Weiner told Bloomberg in a live interview.

Tiziana Life Sciences anticipates pivotal Phase 2 Alzheimer's trial results in fall 2024

NEW YORK, Aug. 17, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that Dr. Howard L. Weiner, a thought leader in the field of neurology and immunology, was featured in an exclusive live interview on Bloomberg to discuss the Company's latest announcement on its advancement of the novel foralumab program in Alzheimer's disease following recent U.S. Food and Drug Administration (FDA) Investigational New Drug (IND) clearance. Foralumab is the only fully human anti-CD3 monoclonal antibody in clinical development.

Tiziana Life Sciences Announces Live Bloomberg TV Interview of Renowned Scientist Dr. Howard L. Weiner to Discuss FDA IND Clearance for Intranasal Foralumab in Alzheimer's Disease

Tiziana Life Sciences Ltd (NASDAQ:TLSA) shares added almost 55% in pre-market trading on Tuesday after the biotechnology company announced that its Investigational New Drug (IND) application for intranasal foralumab to be studied in Alzheimer's disease has been approved by the United States Food and Drug Administration (FDA). The company said foralumab is a “potentially groundbreaking” treatment for Alzheimer's because it targets the disease's underlying pathology by addressing the resulting neuroinflammation caused by the accumulation of toxic proteins in the brain.

Tiziana Life Sciences shares skyrocket after FDA greenlights intranasal foralumab for Alzheimer's disease

Tiziana Life Sciences Ltd.'s stock TLSA soared 41% in premarket trade Tuesday, after the microcap biotech said it has received clearance from Food and Drug Administration for its investigational new drug application for intranasal foralumab, a treatment for Alzheimer's disease.

Tiziana Life Sciences' stock soars 41% premarket after FDA clear path for trial of intranasal treatment for Alzheimer's disease

NEW YORK, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for intranasal foralumab to be studied in Alzheimer's disease. Foralumab could be a potentially groundbreaking treatment for Alzheimer's disease, given it targets the disease's underlying pathology by addressing the resulting neuroinflammation caused by the accumulation of toxic proteins in the brain.

Tiziana Life Sciences Announces FDA IND Clearance of Intranasal Foralumab for the Treatment of Alzheimer's Disease

NEW YORK, July 21, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today disclosed the receipt of a notice (the “Notice”) on July 19, 2023 from the Nasdaq Stock Market LLC (“Nasdaq”) that the Company is not currently in compliance with the $1.00 Minimum Bid Price Requirement for continued listing of the Company's common shares on the Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”). The Notice indicated that, consistent with Nasdaq Listing Rule 5810(c)(3)(A), the Company has 180 days, or until January 16, 2024 (the “Compliance Deadline”), to regain compliance with the Minimum Bid Price Requirement by having the closing bid price of the Company's ordinary share's meet or exceed $1.00 per ordinary share for at least ten consecutive business days.

Tiziana Life Sciences Ltd. Receives Nasdaq Deficiency Notice

Tiziana Life Sciences Ltd (NASDAQ:TLSA) said it has appointed chief medical officer Dr Matthew Davis as its new chief operating officer. With the additional role, Tiziana said Davis will further drive the company's growth and strategic initiatives under its executive chairman, founder and interim CEO Gabriele Cerrone.

Tiziana promotes chief medical officer Dr Matthew Davis to chief operating officer

NEW YORK, June 13, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, is pleased to announce the appointment of Matthew Davis, MD, RPh as its new Chief Operating Officer (COO). Dr. Davis, who also serves as the Chief Medical Officer (CMO), will now take on this additional role to further drive the company's growth and strategic initiatives and will report to Gabriele Cerrone, Executive Chairman, Founder, and interim Chief Executive Officer of Tiziana.

Tiziana Life Sciences Promotes Matthew W. Davis, MD, RPh to Chief Operating Officer

Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced a significant update regarding non-active secondary progressive multiple sclerosis (SPMS) patients treated with h intranasal foralumab in the company's expanded access program. A reduction in microglial activation, which is associated with lowered inflammation in the brain, has now been found in five of six patients in three-month PET scans.

News for Tiziana Life Sciences Ltd Stock (TLSA)